Instrument Inactif

Communiqués Cyclacel Pharmaceuticals Inc Nasdaq

Actions

US23254L1089

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

05/06	Bio Green Med Solution, Inc. et Future Nrg Sdn Bhd annoncent des changements au sein de leur conseil d'administration	CI
05/06	Les plus fortes hausses en préouverture	MT

Communiqués

05/06	BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN. BHD.	AQ
04/06	BIO GREEN MED SOLUTION, INC. ANNOUNCES BUSINESS COMBINATION AGREEMENT TO ACQUIRE FUTURE NRG SDN. BHD.	AQ
14/05	BIO GREEN MED SOLUTION REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE	AQ
30/03	BIO GREEN MED SOLUTION REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE	AQ
13/11	Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update	AQ
12/09/25	Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.	AQ
02/09/25	Cyclacel Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3)	PU
02/09/25	Cyclacel Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3)	PU
02/09/25	Cyclacel Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3)	PU
05/08/25	CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB	AQ
16/07/25	CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY	AQ
07/07/25	CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER	AQ
07/07/25	CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT	AQ
03/06/25	CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT	AQ
15/05/25	CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE	AQ
07/05/25	CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT	AQ
06/05/25	CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. BHD. ITS WHOLLY-OWNED SUBSIDIARY TO ACCELERATE GROWTH AND STOCKHOLDER VALUE	AQ
06/01/25	Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar	AQ
15/11/24	Cyclacel Pharmaceuticals : ANNOUNCES CLOSING OF EXERCISE OF WARRANTS FOR $2.1 MILLION GROSS PROCEEDS Form 8 K	PU
12/11/24	Cyclacel Pharmaceuticals : Change in Certifying Accountants Form 8 K	PU
12/11/24	Cyclacel Pharmaceuticals : Reports THIRD quarter financial results and provides business update Form 8 K	PU
25/10/24	Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule	AQ
24/10/24	Cyclacel Pharmaceuticals : ANNOUNCES That NASDAQ GRANTED AN EXTENSION TO REGAIN COMPLIANCE WITH THE EQUITY STANDARD RULE Form 8 K	PU
24/10/24	Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium	AQ
05/09/24	Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference	AQ